Melior Enters Research Collaboration With Pfizer

EXTON, Pa., April 9 /PRNewswire-FirstCall/ -- Melior Discovery, Inc.
announced today that it has signed an agreement with Pfizer, Inc., under
which Melior's in vivo theraTRACE indications discovery platform will be
used to evaluate the activity of selected Pfizer compounds.
"Our agreement represents a significant opportunity for Melior to
deliver value to Pfizer through the application of our unique and
innovative in vivo testing platform," said Andrew Reaume, PhD, President
and CEO of Melior. "We look forward to a productive collaboration."
Melior Discovery Overview
Melior Discovery is leading the transformation of pharmaceutical drug
repositioning with its unique theraTRACE platform of multiplexed in vivo
models. It is using this capability to both build an internal pipeline of
development candidates as well as sharing this capability with pharma and
biotechnology company partners. In the former case, Melior is identifying
"privileged" compounds that have been discontinued by others which it
identifies through a close working relationship with Dr. Christopher
Lipinski. In its partnered arrangements, Melior offers pharmaceutical
partners an approach to expand their late-stage pipelines with safe,
high-quality drug candidates.

SOURCE Melior Discovery, Inc.

EXTON, Pa., April 9 /PRNewswire-FirstCall/ -- Melior Discovery, Inc.
announced today that it has signed an agreement with Pfizer, Inc., under
which Melior's in vivo theraTRACE indications discovery platform will be
used to evaluate the activity of selected Pfizer compounds.
"Our agreement represents a significant opportunity for Melior to
deliver value to Pfizer through the application of our unique and
innovative in vivo testing platform," said Andrew Reaume, PhD, President
and CEO of Melior. "We look forward to a productive collaboration."
Melior Discovery Overview
Melior Discovery is leading the transformation of pharmaceutical drug
repositioning with its unique theraTRACE platform of multiplexed in vivo
models. It is using this capability to both build an internal pipeline of
development candidates as well as sharing this capability with pharma and
biotechnology company partners. In the former case, Melior is identifying
"privileged" compounds that have been discontinued by others which it
identifies through a close working relationship with Dr. Christopher
Lipinski. In its partnered arrangements, Melior offers pharmaceutical
partners an approach to expand their late-stage pipelines with safe,
high-quality drug candidates.
SOURCE Melior Discovery, Inc.